CliffBio
biologic

Daxxify

daxibotulinumtoxinA-lanm

Loss of exclusivitySeptember 2034projected — 12-year biologic exclusivity estimate
CompanyRevance Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameDaxxify
Active ingredientdaxibotulinumtoxinA-lanm
Strength50UNITS
Dosage formFor Injection
RouteIntramuscular
ModalityBiologic
FDA approvalSeptember 2022
Marketing statusRx

More from Revance Therapeutics

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.